MA48709A - Conjugués de médicament à base de silicium et leurs procédés d'utilisation - Google Patents
Conjugués de médicament à base de silicium et leurs procédés d'utilisationInfo
- Publication number
- MA48709A MA48709A MA048709A MA48709A MA48709A MA 48709 A MA48709 A MA 48709A MA 048709 A MA048709 A MA 048709A MA 48709 A MA48709 A MA 48709A MA 48709 A MA48709 A MA 48709A
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- silicon
- methods
- medicinal products
- based medicinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/42—Block-or graft-polymers containing polysiloxane sequences
- C08G77/452—Block-or graft-polymers containing polysiloxane sequences containing nitrogen-containing sequences
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
- A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D183/00—Coating compositions based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon only; Coating compositions based on derivatives of such polymers
- C09D183/04—Polysiloxanes
- C09D183/08—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/22—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen
- C08G77/28—Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen and oxygen sulfur-containing groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562160575P | 2015-05-12 | 2015-05-12 | |
US201562173002P | 2015-06-09 | 2015-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA48709A true MA48709A (fr) | 2020-04-08 |
Family
ID=57248538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA048709A MA48709A (fr) | 2015-05-12 | 2016-05-12 | Conjugués de médicament à base de silicium et leurs procédés d'utilisation |
Country Status (7)
Country | Link |
---|---|
US (3) | US9931407B2 (fr) |
EP (1) | EP3294810A4 (fr) |
JP (3) | JP6987641B2 (fr) |
AU (3) | AU2016262107B2 (fr) |
CA (1) | CA2985823A1 (fr) |
MA (1) | MA48709A (fr) |
WO (1) | WO2016183359A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA48709A (fr) | 2015-05-12 | 2020-04-08 | Blinkbio Inc | Conjugués de médicament à base de silicium et leurs procédés d'utilisation |
WO2017025057A1 (fr) * | 2015-08-11 | 2017-02-16 | Coherent Biopharma | Conjugués de médicament multi-ligands et leurs utilisations |
EP3791897A1 (fr) * | 2016-02-29 | 2021-03-17 | Madrigal Pharmaceuticals, Inc. | Conjugués de type inhibiteur de hsp90-médicament |
JP2019517564A (ja) * | 2016-06-09 | 2019-06-24 | ブリンクバイオ インコーポレイテッド | シラノール系治療的ペイロード |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
WO2019001550A1 (fr) * | 2017-06-30 | 2019-01-03 | 北京键凯科技股份有限公司 | Derive de polyéthylèneglycol multibranche, à terminaison à plusieurs ramifications, utilisé dans des réactions de chimie click |
CN109206610B (zh) * | 2017-06-30 | 2020-06-30 | 北京键凯科技股份有限公司 | 一种适用于点击化学反应的多臂多爪聚乙二醇衍生物 |
EP3649184A1 (fr) * | 2017-07-06 | 2020-05-13 | The Procter and Gamble Company | Composés de silicone |
US20220402947A1 (en) * | 2018-02-17 | 2022-12-22 | Arrowhead Pharmaceuticals, Inc. | Trialkyne Linking Agents and Methods of Use |
TWI705813B (zh) | 2019-05-24 | 2020-10-01 | 國立交通大學 | 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途 |
JP7310894B2 (ja) * | 2019-08-09 | 2023-07-19 | 信越化学工業株式会社 | 第1級アミノシロキサン化合物の製造方法 |
JP2021028321A (ja) * | 2019-08-09 | 2021-02-25 | 信越化学工業株式会社 | アミノ基含有有機ケイ素化合物の製造方法 |
CN110922551B (zh) * | 2019-10-29 | 2021-09-14 | 温州大学 | 一种用于铁离子检测的罗丹明-聚氨酯荧光探针的制备方法 |
JP7349578B2 (ja) | 2020-10-27 | 2023-09-22 | エルシダ オンコロジー, インコーポレイテッド | 葉酸受容体に標的化されたナノ粒子薬物コンジュゲートおよびその使用 |
CN112940044B (zh) * | 2021-02-04 | 2023-07-04 | 厦门大学 | 一种黄连素偶联顺铂化合物及其制备方法和应用 |
WO2023161296A1 (fr) | 2022-02-22 | 2023-08-31 | Adc Therapeutics Sa | Procédé de conjugaison impliquant une transglutaminase au niveau de la région fc comprenant un n-glycane tronqué |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998054255A1 (fr) | 1997-05-30 | 1998-12-03 | Shiseido, Co., Ltd. | Copolymere contenant des groupes silyles reactifs, compositions contenant ce copolymere et methode de traitement afferente |
DE60331860D1 (en) * | 2002-12-30 | 2010-05-06 | Nektar Therapeutics | Mehrarmige polypeptid-poly(ethylenglykol)-blockcopolymere als arzneistoffzufuhrvehikel |
US20100159446A1 (en) | 2007-07-27 | 2010-06-24 | Haff Lawrence A | Detection Assays and Use Thereof |
CA2700905C (fr) | 2007-10-16 | 2015-02-10 | Bionumerik Pharmaceuticals, Inc. | Analogues de camptothecine substitues en c7 |
US7687496B2 (en) | 2007-10-16 | 2010-03-30 | Bionumerik Pharmaceuticals, Inc. | C7-substituted camptothecin analogs |
ES2396366T3 (es) | 2007-12-10 | 2013-02-21 | Concert Pharmaceuticals Inc. | Inhibidores heterocíclicos de quinasas |
JP2011516547A (ja) | 2008-04-09 | 2011-05-26 | コーネル ユニバーシティー | コフェロンならびにその作製および使用方法 |
US20120045396A1 (en) * | 2009-01-15 | 2012-02-23 | Board Of Regents Of The University Of Texas System | Porous structures with modified biodegradation kinetics |
EP2443125B1 (fr) | 2009-06-17 | 2014-11-26 | Threshold Pharmaceuticals, Inc. | Dérivés de la camptothécine |
WO2011043817A1 (fr) | 2009-10-07 | 2011-04-14 | Cornell University | Coférons et procédés de fabrication et d'utilisation de ceux-ci |
US9233163B2 (en) * | 2010-12-28 | 2016-01-12 | The Children's Hospital Of Philadelphia | Hydrolytically releasable prodrugs for sustained release nanoparticle formulations |
EP2694707B1 (fr) | 2011-04-07 | 2018-08-15 | Cornell University | Monomères aptes à dimériser dans une solution aqueuse et leurs procédés d'utilisation |
EP2693883B1 (fr) | 2011-04-07 | 2018-12-26 | Cornell University | Monomères silyles aptes à former un multimère dans une solution aqueuse et leurs procédés d'utilisation |
WO2012139134A2 (fr) | 2011-04-07 | 2012-10-11 | Coferon, Inc. | Procédés de modulation des protéines de fusion oncogènes |
US20140161729A1 (en) | 2011-04-07 | 2014-06-12 | Cornell University | Cofluorons and methods of making and using them |
WO2013033269A1 (fr) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Monomères bioorthogonaux capables de se dimériser et de cibler des bromodomaines et procédés d'utilisation correspondant |
WO2013033268A2 (fr) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Ligands bromodomaines bivalents et procédés d'utilisation de ceux-ci |
RU2015129800A (ru) * | 2012-12-21 | 2017-01-30 | Биоэллаенс К. В. | Гидрофильные саморазрушающиеся линкеры и их конъюгаты |
EP2968599A4 (fr) * | 2013-03-14 | 2016-11-09 | Albany Molecular Res Inc | Conjugués ligand-agent thérapeutiques et lieurs à base de silicium |
US20150080570A1 (en) | 2013-04-11 | 2015-03-19 | Coferon, Inc. | Alpha,beta-unsaturated monomers capable of multimerization in an aqueous solution, and methods of using same |
US20150087043A1 (en) | 2013-04-11 | 2015-03-26 | Coferon, Inc | Monomers capable of multimerizing in an aqueous solution that employ bioorthogonal chemistries, and methods of using same |
MA48709A (fr) | 2015-05-12 | 2020-04-08 | Blinkbio Inc | Conjugués de médicament à base de silicium et leurs procédés d'utilisation |
JP2019517564A (ja) | 2016-06-09 | 2019-06-24 | ブリンクバイオ インコーポレイテッド | シラノール系治療的ペイロード |
-
2016
- 2016-05-12 MA MA048709A patent/MA48709A/fr unknown
- 2016-05-12 WO PCT/US2016/032177 patent/WO2016183359A1/fr active Application Filing
- 2016-05-12 JP JP2017559591A patent/JP6987641B2/ja active Active
- 2016-05-12 CA CA2985823A patent/CA2985823A1/fr not_active Abandoned
- 2016-05-12 EP EP16793552.7A patent/EP3294810A4/fr not_active Withdrawn
- 2016-05-12 AU AU2016262107A patent/AU2016262107B2/en active Active
-
2017
- 2017-04-03 US US15/477,721 patent/US9931407B2/en active Active
-
2018
- 2018-02-06 US US15/889,638 patent/US11291731B2/en active Active
-
2021
- 2021-04-19 AU AU2021202329A patent/AU2021202329A1/en not_active Abandoned
- 2021-12-01 JP JP2021195154A patent/JP7195402B2/ja active Active
-
2022
- 2022-02-16 US US17/673,475 patent/US20230000993A1/en not_active Abandoned
- 2022-12-13 JP JP2022198694A patent/JP2023021283A/ja active Pending
-
2023
- 2023-05-29 AU AU2023203341A patent/AU2023203341A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2023203341A1 (en) | 2023-06-22 |
JP2018528156A (ja) | 2018-09-27 |
US20230000993A1 (en) | 2023-01-05 |
EP3294810A4 (fr) | 2019-01-02 |
CA2985823A1 (fr) | 2016-11-17 |
JP2023021283A (ja) | 2023-02-10 |
AU2021202329A1 (en) | 2021-05-13 |
US9931407B2 (en) | 2018-04-03 |
JP7195402B2 (ja) | 2022-12-23 |
JP2022028904A (ja) | 2022-02-16 |
US20190290771A1 (en) | 2019-09-26 |
JP6987641B2 (ja) | 2022-01-05 |
US20170202970A1 (en) | 2017-07-20 |
EP3294810A1 (fr) | 2018-03-21 |
AU2016262107A1 (en) | 2017-11-30 |
AU2016262107B2 (en) | 2021-01-21 |
US11291731B2 (en) | 2022-04-05 |
WO2016183359A1 (fr) | 2016-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA48709A (fr) | Conjugués de médicament à base de silicium et leurs procédés d'utilisation | |
MA45280A (fr) | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA47499A (fr) | Anticorps anti-tau et leurs procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA44490A (fr) | Adhésifs biocompatibles et leurs procédés d'utilisation | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA44955A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation |